Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

153

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	6.15M 7.12M 5.66M 5.3M 9.93M 676M 10.09M 66.87M 26.07M 329M 26.7M 26.14M 1.14B	P/E Ratio 2023	-3.09x	P/E Ratio 2024	-0.95x
Enterprise Value	59.25M 68.6M 54.6M 51.1M 95.77M 6.52B 97.25M 645M 251M 3.17B 257M 252M 10.99B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
01/10/25	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

CARMAT Stock OTC Markets

Stocks

CKMTF

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	02/01/2017
Michael Mack BRD	Director/Board Member	79	20/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-50.96%	-54.87%	-	-	7.08M
STRYKER CORPORATION	+2.49%	+2.13%	-17.96%	+11.52%	117B
SMITH & NEPHEW PLC	-0.31%	-1.22%	+2.12%	-4.39%	12.86B
GLAUKOS CORPORATION	+2.41%	+1.83%	+30.42%	+90.18%	7.29B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-3.51%	-46.74%	-69.06%	4.12B
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+5.59%	+11.04%	+33.01%	2.49B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.30%	-16.96%	-14.78%	1.7B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-6.39%	+3.63%	-11.43%	1.63B
L&C BIO CO.,LTD	-8.89%	-8.45%	+165.17%	+112.14%	1.49B
Average	-4.89%	+1.07%	+16.34%	+18.40%	18.59B
Weighted average by Cap.	+2.14%	+1.39%	-12.08%	+12.58%

	2023	2024
Net sales	3.84M 4.44M 3.54M 3.31M 6.2M 422M 6.3M 41.75M 16.28M 206M 16.67M 16.32M 712M	7.34M 8.5M 6.77M 6.33M 11.87M 808M 12.06M 79.91M 31.16M 393M 31.91M 31.23M 1.36B
Net income	-53.87M -62.37M -49.64M -46.47M -87.08M -5.93B -88.43M -586M -229M -2.89B -234M -229M -9.99B	-51.4M -59.51M -47.36M -44.33M -83.08M -5.66B -84.37M -559M -218M -2.75B -223M -219M -9.53B
Net Debt	49.64M 57.47M 45.74M 42.81M 80.24M 5.46B 81.48M 540M 211M 2.66B 216M 211M 9.21B	53.1M 61.48M 48.93M 45.8M 85.84M 5.84B 87.17M 578M 225M 2.84B 231M 226M 9.85B